Welcome to our dedicated page for WW International news (Ticker: WW), a resource for investors and traders seeking the latest updates and insights on WW International stock.
WW International, Inc. (WeightWatchers), trading under the symbol WW, is frequently in the news for developments in science-backed weight management, clinical programs, and digital health innovation. Company announcements emphasize its role as a global leader in weight health, combining behavioral programs, clinical care, GLP‑1 medications when appropriate, and technology-enabled support.
News about WeightWatchers often covers updates to its integrated GLP‑1 platform, including the WeightWatchers Med+ program and the GLP‑1 Success behavioral support experience. Releases have highlighted access to FDA‑approved GLP‑1 treatments, such as an oral formulation of Wegovy, and the company’s positioning as a NovoCare Recognized Care Provider. These stories focus on how WeightWatchers pairs medication access with evidence‑based nutrition, coaching, and community to improve outcomes.
Investors and observers will also find coverage of new product and feature launches within the WeightWatchers app, such as the Weight Health Score, AI Body Scanner, fitness content partnerships, and configurable Modes that adjust support as members move from weight loss to maintenance. Additional news items include the launch of specialized programs like WeightWatchers for Menopause, the publication of WeightWatchers for Business annual results, collaborations with partners like Amazon Pharmacy, and the introduction of the WeightWatchers Awards for health and wellness products.
On this news page, readers can track earnings announcements, conference participation, leadership appointments, and strategic initiatives related to WeightWatchers’ transformation in the GLP‑1 era. For those following WW stock or the broader weight health sector, the news feed provides a centralized view of how the company is evolving its behavioral and clinical businesses, expanding partnerships, and refining its global weight management platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
WW International, Inc. (NASDAQ: WW) will announce its first quarter 2023 results on May 4, 2023, after market close. A conference call will follow at 5:00 p.m. ET, featuring CEO Sima Sistani and Interim Principal Financial Officer Heather Stark discussing the results and responding to investor queries.
The call will be accessible via a live webcast on the Company's corporate website, with supplemental materials made available beforehand. A replay of the webcast will be accessible for approximately 90 days.
WW International (NASDAQ: WW) has successfully acquired Weekend Health, Inc., a telehealth platform focused on chronic weight management. This acquisition aims to enhance WW's capabilities by integrating medication management and clinical care, aligning with the company's strategy to expand its market presence. WW's CEO, Sima Sistani, emphasized the importance of integrating clinical interventions for individuals qualified for medication. This step is expected to provide sustainable, science-backed weight health solutions, acknowledging the advancements in chronic weight management medications.
WW International, Inc. (NASDAQ: WW) announced significant changes to its Board of Directors as part of the preparations for the 2023 Annual Meeting on May 9, 2023. Chairman Raymond Debbane and Director Jonas Fajgenbaum will not seek re-election. Thilo Semmelbauer, who has been a Board member since 2016, has been appointed as the new Chairman effective May 9, 2023. Debbane, in his statement, highlighted WW's evolution over 23 years and expressed confidence in Semmelbauer's leadership. Semmelbauer has extensive experience, including previous roles within WW and as Managing Director at Insight Partners.
WW International, Inc. (NASDAQ: WW) reported its fourth quarter and full year fiscal 2022 results, highlighting an operating loss of $50.8 million and $283.0 million for the quarter and year respectively. Revenues decreased to $223.9 million in Q4 2022, a decline of 18.8% year-over-year, primarily due to a 14.9% drop in subscribers, totaling 3.5 million. The company also announced the acquisition of Sequence, a digital health platform valued at $132 million. Adjusted operating income for Q4 was $24.2 million, down 55.8% year-over-year. The Q1 2023 revenue guidance stands at approximately $235 million, with a projected operating loss of $30 to $35 million.
FAQ
What is the current stock price of WW International (WW)?
What is the market cap of WW International (WW)?
